Brief CorrespondenceThe Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers☆
References (11)
- et al.
A 16-yr follow-up of the European Randomized study of Screening for Prostate Cancer
Eur Urol
(2019) - et al.
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
Lancet
(2014) - et al.
Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
Eur Urol
(2014) - et al.
Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC)
Eur Urol
(2006) - et al.
Estimate of opportunistic prostate specific antigen testing in the Finnish randomized study of screening for prostate cancer
J Urol
(2017)
There are more references available in the full text version of this article.
Cited by (5)
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study
2023, Prostate Cancer and Prostatic DiseasesPopulation-based estimates of age and comorbidity specific life expectancy: a first application in Swedish males
2022, BMC Medical Informatics and Decision MakingPSA screening—a matter of debate?
2019, Memo - Magazine of European Medical Oncology
- ☆
Please visit www.eu-acme.org/europeanurology to read and answer questions on-line. The EU-ACME credits will then be attributed automatically.
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.